

PATENT COOPERATION TREATY
PCT
THIRD PARTY OBSERVATION
(PCT Administrative Instructions Part 8)

Applicant's or agent's file reference 4250-106PCT	
International application number PCT/CA2022/050468	International filing date (day/month/year) 29 Mar 2022 (29/03/2022)
Applicant MYND LIFE SCIENCES INC.	
Third party observation submitted by Taylor KURTZWEIL	Observation submitted on behalf of Porta Sophia
Date of submission(day/month/year) 23 Nov 2022 (23/11/2022)	Language of observation English

Basis and contents of observation

1. The observation is made on the basis of the claims in the international application as filed.
2. The observation comprises:
References to documents: 2
Uploaded copies of documents: 0
3. Further explanations:
Uploaded copies of documents: 0

Citation # 1 (Patent/utility model) (# uploaded documents: 0):

Country code: WO	Publication number: 2022/094719	Document kind code: A1	
Patent Applicant/Patent Owner: Pacific Myco Biosciences LTD.		Title of invention: A Method of Treating Depression by Immune Modulation	
Link to document:			
Publication Date: 12 May 2022 (12/05/2022)	Filing Date: 11 May 2021 (11/05/2021)	Priority Date: 06 Nov 2020 (06/11/2020)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 1, 4, 14, 17, 18		Relevant to Claims: 1-10	
<p>Brief explanation of relevance:</p> <p>From claim 1 "A method of inhibiting neuroinflammation in a patient in need thereof, said method comprising administering an agonist of ABCF1."; relevant to WO2022204802 claim 1</p> <p>From claim 4 "The method of claim 3, wherein the one or more symptoms are selected from the group consisting of trouble concentrating, remembering details, and making decisions; fatigue; feelings of guilt, worthlessness, and helplessness; pessimism and hopelessness; insomnia, early-morning wakefulness, or sleeping too much; irritability; restlessness; loss of interest in things once pleasurable, including sex; overeating, or appetite loss; aches, pains, headaches, or cramps that won't go away; digestive problems that don't get better, even with treatment; persistent sad, anxious, or "empty" feelings; suicidal thoughts or attempts and combinations thereof."; relevant to WO2022204802 claim 2</p> <p>From claim 14 "The method of any one of claims 1, 3 to 9, 11 and 13, wherein the agonist is psilocibin, psilocin or an analog or derivative thereof."; relevant to WO2022204802 claims 3, 4, 5, 6, 7</p> <p>From claim 15 "The method of any one of claims 1, 3 to 9, 11 and 13, wherein the agonist is Psilocin, Psilocibin, 4-Acetoxy-N, N-dimethyltryptamine, O-Acetyl Psilocin Fumerate, and 4-acetoxyindole."; relevant to WO2022204802 claims 3, 4, 5, 6, 7</p> <p>From claim 17 "The method of any one of claims 1, 3 to 9, 11 and 13, further comprising administration of another therapeutic agent."; relevant to WO2022204802 claims 8, 10</p> <p>From claim 18 "The method of claim 13, wherein the inflammation is neuroinflammation" relevant to WO2022204802 claim 9</p>			

Citation # 2 (Patent/utility model) (# uploaded documents: 0):

Country code: WO	Publication number: 2020/212948	Document kind code: A1	
Patent Applicant/Patent Owner: Compass Pathfinder Limited		Title of invention: Methods of Treating Neurocognitive Disorders, Chronic Pain and Reducing Inflammation	
Link to document:			
Publication Date: 22 Oct 2020 (22/10/2020)	Filing Date: 17 Apr 2020 (17/04/2020)	Priority Date: 17 Apr 2019 (17/04/2019)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 1, 3, 42, 52; pages 63-64 lines 31-2		Relevant to Claims: 2, 4, 5, 7-12	
Brief explanation of relevance: <p>From claim 1 "A method for treating one or more neurocognitive disorders in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of psilocybin or an active metabolite thereof."; relevant to WO2022204802 claims 4, 8, 10</p> <p>From claim 3 "The method of claim 1, wherein the neurocognitive disorder is due to, one or more of Alzheimer's disease, Lewy Body Dementia, Traumatic Brain Injury, Prion Disease, HIV Infection, Parkinson's disease, or Huntington's disease."; relevant to WO2022204802 claim 11</p> <p>From claim 42 "The method of any one of embodiments 1 -40, wherein reducing inflammation in the subject treats or prevents one or more of allergy, asthma, Alzheimer's disease, diabetes, cardiovascular disease, sepsis, arthritis, joint disease, inflammatory bowel disease, or dermatitis in the subject."; relevant to WO2022204802 claims 2, 5, 7</p> <p>From claim 52 "The method of any one of claims 47-49, wherein reducing inflammation in the subject treats or prevents one or more of allergy, asthma, Alzheimer's disease, diabetes, cardiovascular disease, sepsis, arthritis, joint disease, inflammatory bowel disease, or dermatitis in the subject."; relevant to WO2022204802 claims 2, 9, 11</p> <p>From pages 63-64 lines 31-2 "In some embodiments, the neurocognitive disorder is caused by a degenerative disorder, such as Alzheimer's disease (also called senile dementia, Alzheimer type), Creutzfeldt-Jakob disease, Diffuse Lewy body disease, Huntington's disease, Multiple sclerosis, Normal pressure hydrocephalus, Parkinson's disease, or Pick disease. In some embodiments, the neurocognitive disorder is due to one or more of Alzheimer's disease, Lewy Body Dementia, Traumatic Brain Injury, Prion Disease, HIV Infection, Parkinson's disease, or Huntington's disease"; relevant to WO2022204802 claims 11, 12</p>			